Case 2: RET+ Metastatic Medullary Thyroid Cancer
Lori Wirth, MD, presents the case of a 60-year-old man with RET+ metastatic medullary thyroid cancer.
Clinical Trials of BTKi in B-Cell Lymphomas
Drs Shadman and Cohen discuss clinical trial data utilizing acalabrutinib in B-cell lymphomas.
Comparing Ibrutinib, Acalabrutinib, and Zanubrutinib BTKi
Two experts compare experiences and data concerning use of ibrutinib, acalabrutinib, and zanubrutinib in B-cell lymphomas.
Lenvatinib: Dose Considerations
Marcia Brose, MD, discusses the efficacy and safety data of a phase 2 trial examining lenvatinib dose reductions in patients with RAI-DTC.
SELECT Trial: Post-Hoc Analysis
Andrew Gianoukakis, MD, and Lori Wirth, MD, examine post-hoc analysis data from the phase 3 SELECT trial.
Ibrutinib Clinical Trials for B-Cell Lymphomas
Drs Shadman and Cohen provide an overview of clinical trials utilizing the BTK inhibitor, ibrutinib, for B-cell lymphomas.
Available BTKi and Their Mechanisms of Action
Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, introduce available BTK inhibitors used as targeted therapy in B-cell malignancies.
CD19-Targeted mAbs in RR DLBCL Using Loncastuximab Tesirine
The doctors switch their monoclonal antibody conversation’s focus to longcastuximab tesirine for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
CD19-Targeted mAbs in R/R DLBCL Using Tafasitamab Continued
The discussion of tafasitamab as a monoclonal antibody therapy option for relapsed/refractory diffuse large B-cell lymphoma continues.
DTC Key Efficacy and Safety Data
Dr Andrew Gianoukakis reviews the study design and key efficacy data of the phase 3 DECISION and SELECT trials.
Thyroid Cancer Treatment Guidelines
Andrew Gianoukakis, MD, reviews the NCCN guidelines for the treatment of patients with thyroid cancer.
RR-DTC Systemic Therapy Considerations
Dr Andrew Gianoukakis, explores considerations surrounding systemic therapy in patients with RAI-refractory differentiated thyroid cancer.
RR-DTC: Molecular Testing Considerations
Marcia Brose, MD and Lori Wirth, MD, discuss molecular testing considerations in patients with radioiodine-refractory DTC.
RAI Treatment: Impact of Mutation Status
Experts in the management of thyroid cancer discuss radioactive iodine therapy and the clinical implications of mutational status in RAI- refractory DTC.
RR-DTC: Definition and Clinical Presentation
The panel of experts share their insights into the definition and clinical presentation of radioiodine-refractory DTC.
Case 1: Treatment Considerations for Refractory DTC
Andrew Gianoukakis, MD, reviews the treatment and management options for a 71-year-old woman with RAI- refractory differentiated thyroid cancer.
Case 1: Considerations of RAI Use
Experts in thyroid cancer discuss treatment considerations surrounding the use of radioiodine therapy in patients with thyroid cancer.
Case 1: RAI-Refractory DTC
Andrew Gianoukakis, MD, reviews the case of a 71-year-old woman with RAI-refractory differentiated thyroid cancer and the panel discuss relevant clinical trial data.
Potential Case Outcomes for 65-Year-Old Man With mCRC
Tanios Bekaii-Saab, MD, FACP, concludes with a discussion of potential outcomes for a 65-year-old patient with stage 4 metastatic colorectal cancer.
Subsequent Lines of Therapy and Non-Chemotherapy Options for mCRC
Dr Bekaii-Saab reviews options for subsequent lines of therapy for metastatic colorectal cancer, including non-chemotherapy options.
Capecitabine/Bevacizumab and Signs of Progression/Recurrence for mCRC
An expert elaborates on the importance of the capecitabine + bevacizumab combination therapy for metastatic colorectal cancer, as well as what signs of progression or recurrence to look for in patients.
First-Line Therapy Options for mCRC
Dr Bekaii-Saab discusses therapy options for first-line treatment of metastatic colorectal cancer.
Overview: A 65-Year-Old Man with Metastatic Colorectal Cancer
Tanios Bekaii-Saab, MD, FACP, provides an overview of a case involving a 65-year-old man diagnosed with stage 4 metastatic colorectal cancer.
CD19-Targeted mAbs in R/R DLBCL Using Tafasitamab
Dr Mazyar Shadman and Dr Brian T. Hill focus on CD19 being targeted in monoclonal antibody therapy options for relapsed/refractory diffuse large B-cell lymphoma, specifically tafasitamab.
CD19 As a Targeted Agent in CAR T Cell Therapy for R/R DLBCL
Drs Shadman and Hill discuss using CD19 as a targeted therapy option in CAR T cell therapy for relapsed/refractory diffuse large B-cell lymphoma.
Treatment Methods: Transplant Eligibility in R/R DLBCL and CAR T Cell Therapy
The experts delve further into treatment methods for relapsed/refractory diffuse large B-cell lymphoma, particular for transplant-eligible and -ineligible patients.
An Introduction to DLBCL: Current Approaches and Challenges
Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, explain the intricacies of the diffuse large B-cell lymphoma treatment landscape.
Regorafenib Sequencing and the Future of Metastatic Colorectal Cancer Management
John Marshall, MD, speaks on regorafenib sequencing and relays his thoughts on the future of treatment for metastatic colorectal cancer.
Regorafenib as a Metastatic Colorectal Cancer Therapy Option
Dr Marshall discusses the impact regorafenib has had in the treatment of metastatic colorectal cancer and describes data from the CORRECT and ReDOS clinical trials.
Progression on Metastatic Colorectal Cancer Treatment
A gastrointestinal cancers expert describes monitoring strategies for progression of metastatic colorectal cancer.